We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/10/2022 08:56 | I think we large orders being filled in the usual very professional way, and that is all that is causing this slide - this will soon be reversed imo as supply drys up and the buyer is forced to pay more. | clocktower | |
13/10/2022 08:56 | I think we have large orders being filled in the usual very professional way, and that is all that is causing this slide - this will soon be reversed imo as supply drys up and the buyer is forced to pay more. | clocktower | |
13/10/2022 08:50 | I was too, very professional and clearly running a tight ship.. there a lot to look forward to over the coming weeks months years | givmesunshine | |
13/10/2022 08:18 | I was impressed with the whole presentation, as I was on the previous occasion. As for royalties, it seems that once certain targets are reached the percentage will increase substantially, which gives rise to even greater rewards over time. I was doubting the board after many months without news last time about buying shares but I was wrong to do so. It is clear the lady they introduced is a deal maker and a very good one at that, and there clearly are other avenues opening up for more deals to be struck. Hopefully they get pulled off at advantage terms but with this one in the bag I it gives the company more strength to negotiate from. | clocktower | |
13/10/2022 08:08 | Whats the tohughts on royalties? appears these are over and above the core $160 million milestone.. a way of but still unbelieveable for a 14.8 miliion mktcap bio | givmesunshine | |
13/10/2022 07:28 | Morning Nice new thread - doesn't stop the nutters though .. Advfn is a poor site now | givmesunshine | |
13/10/2022 07:24 | Thanks F911, I was going to tell you to create a premium thread yesterday. GL | firestorm911 | |
13/10/2022 07:05 | Looks like better language! GLA | ali g2 | |
13/10/2022 06:23 | Cheers and welcome. | clocktower | |
13/10/2022 06:20 | Well done ! | amaretto1 | |
12/10/2022 19:23 | what is with these boards ? ADVFN Dead | givmesunshine | |
12/10/2022 18:30 | Hi All Worth Reading Stalicas stance on this deal - take a look at thier team also - one thing the caught my eye is the end royalties are over and above the £160m milestones? They are perpares to fund this fully also - its a big deal IMO GENEVA, Oct. 10, 2022 /PRNewswire/ -- STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-charact STALICLA's unique approach addresses a major weakness in the drug development process for NDDs and neuropsychiatric disorders: behaviour is a terrible biomarker. Thanks to DEPI, a proprietary platform aggregating molecular data and human genetic information, STALICLA pushes the frontier of precision medicine further into precision NDDs. DEPI has already reached validation through the clinical identification of biologically defined subgroups of patients with ASD, and their respective candidate treatments. SFX-01 will strengthen STALICLA's pipeline to advance precision medicine for a new subgroup of patient with Autism Spectrum Disorder. SFX-01 is a patented composition of sulforaphane and alpha cyclodextrin, and the only grade of sulforaphane suitable for clinical research and possible approval as medicine. Thanks to DEPI, STALICLA identified SFX-01 as the best treatment candidate for its second subgroup of patients, ASD-Phenotype 2. SFX-01 in-licensing follows the completion, in early 2022, of Phase 1b for STP1, Stalicla's lead candidate tailored to ASD-Phenotype1, a first subgroup of patients identified by DEPI. | givmesunshine | |
12/10/2022 17:38 | Givemesunshine The problem with Aim shares is liquidity and large shareholders. That's how and why shorter hammer the share from IPO. It's because of illiquid shares. Tight holding is terrible news. | firestorm911 | |
12/10/2022 17:12 | In a year or two, I expect those same traders will be looking at this stock and working out what they would have made by making a lasting investment, rather than day/week trading. To be fair I do both. I have set investments that I hold long term, and on news I buy small amounts and trade them to keep the mind active and for a bit of fun but I still hold a pot until they reach a figure that I think I can find better use of the money (some fail though, so not all roses like this one. Good Luck though if it works for you firestorm911. | clocktower | |
12/10/2022 17:01 | It's all to be expected .. but a large proportion of shares not in public hands 46% - share with institutional holders above 3% - liquidity will dry up but a new base formed and if anyone is adding St traders will be feeding them - company only worth £14 million could understand if burning through cash but they aren't / won't | givmesunshine | |
12/10/2022 16:58 | Most of these penny shares are for momentum trade buddy. Look at all penny shares and aim shares chart. They all follow the same pattern, I would say 95% lose 90% very quickly. They grow mcap by issuing shares capital. People who missed out on selling yesterday or the day before take an opportunity to sell today. That's the nature of the casino in the UK. | firestorm911 | |
12/10/2022 16:34 | A lot of short sighted people on here who clearly are not investors but momentum traders. See the bigger picture ffs, massive gains for the patient is my view. De-risked massively now and as I've said, this autism avenue was not even on the pitch before this week. All to play for. Huw indicated royalties in the double digits region on top of the milestone payments, then quickly change that to higher than double digits. I am a happy holder all the way to the older broker note of around 14p I believe. I might top slice a bit then, but none at all before. Good luck and each to their own but I've waited this long and I am not in a rush now. Pleasant evening all | markth126 | |
12/10/2022 16:28 | Just Added £10k worth, maybe a bit early | givmesunshine | |
12/10/2022 15:52 | Waiting to see if this drops - mms killing the spread and ST sellers may put it down .. either way it's a great but at these levels | givmesunshine |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions